Genmab

	21/9 17:14 af Helge Larsen/PI-redaktør	Novo også drønstærk i dag.
	21/9 17:04 af Mcjean	Yep! Tak til Genmab for at give folk håb.
	21/9 17:01 af Solsen	Imponerende ganske enkelt !
	21/9 17:00 af GeorgeBest	-0,16% er til at holde til på en dag hvor DAX futter er neden med 4,5%
	21/9 16:53 af Don Joning	Det giver jo alt sammen til at lave en robust forretning, med mange ben at stå på og det er jo ikke det nemmeste i verden de udvikler på - det kunne også have været et hard stop uden signifikant effekt og 0 værdi i det område.
	21/9 16:50 af E L	fiercebiotech - ESMO: Seattle Genetics' ADC candidate curbs hard-to-treat cervical cancer - (link)
	21/9 16:47 af GeorgeBest	men tiso kan måske også bruges i andre cancer former. der skulle også komme data på det i år
	21/9 16:46 af GeorgeBest	jo
	21/9 16:46 af Don Joning	ja, men er det ikke 50/50
	21/9 16:46 af GeorgeBest	skal også deles med SGEN
	21/9 16:45 af Don Joning	tak GB det er da alligevel også lidt...
	21/9 16:45 af GeorgeBest	årligt topsalg
	21/9 16:45 af GeorgeBest	Tiso: jeg har set estimater på et topsalg på 750M USD i cervical cancer
	21/9 16:44 af GeorgeBest	knock your socks off data er mere relateret til epcoritamab og PD-L1x4-1BB
	21/9 16:44 af Don Joning	nogen der har nogen bud på hvor værdifuldt tiso i cervical cancer kan blive?
	21/9 16:43 af bikube	Det er da det man forstår ved "late breaking".
	21/9 16:43 af GeorgeBest	der var ikke forventet mere for tiso
	21/9 16:41 af Macabo	ORR 24% og DOR 8,3 måneder - det er godt men ikke knock of socks niveau
	21/9 16:35 af GeorgeBest	thanks E L
	21/9 16:34 af E L	correction for the link GB (link)
	21/9 16:31 af GeorgeBest	The results of the tisotumab vedotin phase 2 clinical trial are encouraging as they demonstrate clinically meaningful, durable responses with a manageable side effect profile
	21/9 16:29 af GeorgeBest	(link)
	21/9 16:28 af GeorgeBest	Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
	21/9 14:55 af E L	(link) Amgen showing bispecific CD3x PSMA , like JNJ-63898081

	21/9 11:14 af Bulder	Could be RA. Has been discussed before. I think Janssen has an unused IND for dara in RA. (link)
	21/9 10:19 af E L	ok. we know Mayo has a Dara trial in CLL, in combination with Ibrutinib, will be interesting to see
	21/9 09:55 af Darvin	EL It was Rajkumar who announced It yesterday. And - depending on how you read the text - I read it as if they will open a trial for various autoimmune diseases - but only my way to read it
	21/9 09:50 af Darvin	Tillykke og godt gået Helge :-D
	21/9 09:45 af Helge Larsen/PI-redaktør	:-)
	21/9 09:45 af Sukkeralf	ATH
	21/9 09:33 af Helge Larsen/PI-redaktør	Styrken er i top: (link)
	21/9 09:26 af Helge Larsen/PI-redaktør	Tak transalp og Pensionist:-)
	21/9 09:21 af Helge Larsen/PI-redaktør	"The treatment beat back cancer in 20 newly diagnosed, never-before-treated patients, shrinking tumors in all of them. And in 45 patients whose disease had worsened despite taking Tagrisso, J&J’s treatment curbed tumor growth in 60% of them and shrank tumors in 36% of them. One patient had a complete response, meaning the drug eliminated all signs of cancer".
	21/9 08:54 af E L	ESMO: Janssen’s anti-EGFR combo tackles lung cancer ahead of phase 3 Tagrisso showdown (link)
	21/9 08:35 af E L	@Darvin for Mayo to start a trial is definately news. Really curious if it will be only for Lupus or also for other autoimmune diseases? The NEJM article attracted a surprisingly large number of positive comments from MDs on twitter over the last few days.
	21/9 08:27 af E L	and since nobody bothered to correct my comment from yesterday evening (even thought i am sure you had all seen the mistake) ; i meant 2 Ph III trials for Amivantamab
	21/9 08:24 af E L	2 more twitter threads on Amivantamab, Stephen V Liu (link) and Joshua Bauml (link)
	21/9 07:30 af bibob	Onc.live : Amivantamab (link)
	21/9 07:19 af transalp	Go morgen.. :) godt at høre det lysner for PI . Tak i lige måde .
	21/9 07:18 af GeorgeBest	Tillykke Helge :-)
	21/9 07:03 af Helge Larsen/PI-redaktør	Servicemeddelelse: Jeg har de seneste uger tegnet nye partneraftaler og et større antal annoncer for det kommende år. Dermed bliver det ikke nødvendigt med donationer længere. På et et tidspunkt vil jeg muligvis indføre et frivilligt support-abonnement til en fast lav pris. Tak for jeres støtte. Uden den - intet PI.
	21/9 06:52 af Helge Larsen/PI-redaktør	God morgen. :-)
	20/9 21:00 af Darvin	Mere - det er det jo nok - og sikker også at MayoClinic starter trial på området
	20/9 20:56 af Darvin	Kan kke huske om dette fra bl.a. Ola Landgren har været nævnt: Ola Landgren, M.D.: Evidence of strong clinical benefit when using CD38 targeted monoclonal antibody (daratumumab) in two patients with refractory, life-threatening Systemic Lupus Erythematosus (SLE). May become an important treatment strategy for many autoimmune diseases in the future?
	20/9 20:55 af peter12	Lidt fra fierce (link)
	20/9 17:47 af E L	Janssen Presents Findings from Global, Multi-Center Trial Examining Amivantamab in Combination with Lazertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer (link)
	20/9 17:47 af E L	@kkjoel IF so, we should find out soon; Amivantamab is also already starting 2 Ph II trials
	20/9 16:21 af GeorgeBest	#Amivantanab in Combination with Lazertinib Exciting data in Osimertinib-resistan pts ORR 36% 6% of discontinuation due AEs Excellent data for the EGFR community (link)
	20/9 15:38 af GeorgeBest	Nice data for$JNJ amivantamab and lazertinib - looks good for post $AZN @TAGRISSO_AZ and also for treatment naïve patients. JNJ certainly has the hope of beating Tagrisso with a head to head phase III. (link)
	20/9 15:36 af GeorgeBest	MET inhibition + double EGFR inhibition is a win. Amivantamab (bispecific EGFR/MET Ab)+ Lazertinib (3rd gen TKI) rescue osimertinib resistant pts with EGFRmut NSCLC: ORR 36%. Will be compared to osi 1st line in a Phase III trial. Dual EGFR/MET tox to be followed... (link)